Correlative data using ex vivo bioassay for treated patients. Plasma samples from patients 101 and 103 to 108 were obtained at the treatment time points noted. Ex vivo bioassay was performed as described above for Figure 2. Results for patients 101 and 103 were based on 40 mg twice-a-day dosing. All other results were from patients treated at 60 mg twice a day, with bars representing data from 80 mg twice-a-day dosing. P indicates peak (1 hour after CEP-701 dose); T, trough (12 hours after dose); number, days on therapy.